The present subject matter relates to a solid oral pharmaceutical composition comprising combination of meloxicam and rizatriptan or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. The present subject matter also relates to a fixed dose pharmaceutical composition comprising meloxicam and rizatriptan or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. Furthermore, it also relates to methods for manufacturing such compositions and use thereof.
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
The present application provides polymorph of Ribociclib citrate salt and pharmaceutical compositions thereof. The present invention also relates to preparation method thereof. In particular, the invention relates to Ribociclib citrate dihydrate.
The present subject matter relates to a solid oral pharmaceutical composition comprising combination of levodopa and carbidopa as an active ingredient and dosage form comprises two types of components, the first components comprises immediate release component (IR component) and the second component comprises controlled release component (CR component).
Described herein are compounds of formula (A) that are useful in the modulation of inflammation and treating associated disorders by acting on TYK2 to cause TYK2-mediated signal transduction inhibition. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, an endocrine disorder, a neurological disorder, a proliferative disorder, or a disorder associated with transplantation.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
The present subject matter relates to a pharmaceutical composition comprising Trametinib or a pharmaceutically acceptable salt thereof and at least one pharmaceutical acceptable excipient. The present subject matter also relates to a solid oral pharmaceutical compositions comprising a solid dispersion of Trametinib or a pharmaceutically acceptable salt thereof and at least one pharmaceutical acceptable excipient. Furthermore, it also relates to methods for manufacturing such compositions, and uses thereof.
Described herein are compounds of formula (I) that are useful in the modulation of inflammation and treating associated disorders by acting on TYK2 to cause TYK2-mediated signal transduction inhibition. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, an endocrine disorder, a neurological disorder, a proliferative disorder, or a disorder associated with transplantation.
A61P 5/00 - Drugs for disorders of the endocrine system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
The present subject matter relates to a solid oral pharmaceutical composition comprising combination of azilsartan and chlorthalidone or a pharmaceutically acceptable salt thereof with at least one pharmaceutically acceptable excipient. The present subject matter also relates to a fixed dose pharmaceutical composition comprising azilsartan and chlorthalidone or a pharmaceutically acceptable salt thereof with at least one pharmaceutically acceptable excipient. Furthermore, it also relates to methods for manufacturing such compositions and use thereof.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/549 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
9.
PHARMACEUTICAL COMPOSITION CONTAINING COMBINATION OF MELOXICAM AND RIZATRIPTAN AND PROCESS OF PREPARATION THEREOF
The present subject matter relates to a solid oral pharmaceutical composition comprising combination of meloxicam and rizatriptan or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. The present subject matter also relates to a fixed dose pharmaceutical composition comprising meloxicam and rizatriptan or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. Furthermore, it also relates to methods for manufacturing such compositions and use thereof.
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
The present invention relates to a continuous process for the preparation of Pregabalin of formula (I), reaction is carried out in an Oscillating Baffled Reactor. NH2COOHCH3CH3Formula (I)
Present disclosure is directed to solid pharmaceutical compositions of ivosidenib or pharmaceutically acceptable salt thereof and process for preparation of such compositions.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
The present invention relates to an improved process of preparation of Ivosidenib a compound of Formula (I). More particularly, present invention provides process of preparation of intermediates. Also provide process of preparation of amorphous form of Ivosidenib. Further, present invention provides process of preparation of chirally pure Ivosidenib a compound of Formula (I).
The present invention relates to an improved process of preparation of Ivosidenib a compound of Formula (I). More particularly, present invention provides process of preparation of intermediates. Also provide process of preparation of amorphous form of Ivosidenib. Further, present invention provides process of preparation of chirally pure Ivosidenib a compound of Formula (I).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
The present subject matter provides amorphous solid dispersions of venetoclax or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising said amorphous solid dispersions. The present subject matter also provides methods for the preparation of said solid dispersions and compositions. The present subject matter further provides pharmaceutical compositions comprising mixture of solid dispersions.
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals, pharmaceutical safety, pharmaceutical misuse and pharmaceutical emergency procedures, all of the foregoing for the pharmaceutical containing acitretin
15.
A SOLID DISPERSION OF PONATINIB HYDROCHLORIDE AND PROCESS OF PREPARATION THEREOF
The present subject matter relates to a solid oral pharmaceutical composition comprising ponatinib or a pharmaceutically acceptable salt thereof and at least one pharmaceutical acceptable excipient. The present subject matter also relates to pharmaceutical compositions comprising a solid dispersion of ponatinib or a pharmaceutically acceptable salt thereof and at least one pharmaceutical acceptable excipient. Furthermore, it also relates to process of preparation of such compositions, and uses thereof.
The present subject matter relates to a solid oral pharmaceutical composition comprising lasmiditan or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the solid oral pharmaceutical composition is prepared by a dry manufacturing process.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
17.
Solid state forms of Venetoclax and its process for the preparation there of
The present invention provides solid state forms of Venetoclax, particularly relates to novel alkali metal salt and/or DMF solvate form of Venetoclax or its salt. The present invention also relates to process for the preparation Venetoclax by using the said solid state form of Venetoclax.
The present invention relates to an improved process of preparation of Ivosidenib a compound of Formula (I). More particularly, present invention provides process of preparation of intermediates. Also provide process of preparation of amorphous form of Ivosidenib. Further, present invention provides process of preparation of chirally pure Ivosidenib a compound of Formula (I).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
19.
Solid state forms of venetoclax and its process for the preparation there of
The present invention provides solid state forms of Venetoclax, particularly relates to novel alkali metal salt and/or DMF solvate form of Venetoclax or its salt. The present invention also relates to process for the preparation Venetoclax by using the said solid state form of Venetoclax.
The present subject matter provides amorphous solid dispersions of venetoclax or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising said amorphous solid dispersions. The present subject matter also provides methods for the preparation of said solid dispersions and compositions. The present subject matter further provides pharmaceutical compositions comprising mixture of solid dispersions.
The application provides process of preparation of benzimidazole compounds such as Binimetinib and Selumetinib. Also, the present application provides intermediates for process of preparation of Binimetinib and Selumetinib.
C07D 235/10 - Radicals substituted by halogen atoms or nitro radicals
C07D 473/04 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present subject matter relates to a ready-to-use or a ready-to-dilute stable liquid composition comprising cyclophosphamide. The present subject matter also relates to a ready-to-use or a ready-to-dilute stable liquid composition comprising cyclophosphamide meant for parenteral administration. The subject matter further relates to a process for preparing such cyclophosphamide composition.
The present subject matter is directed to a stable pharmaceutical composition comprising axitinib in crystalline polymorphic form IV and one or more pharmaceutically acceptable excipients. In particular, the composition is bioequivalent to the commercially available axitinib tablets (INLYTA®).
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 9/00 - Medicinal preparations characterised by special physical form
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
24.
SOLID STATE FORMS OF VENETOCLAX AND ITS PROCESS FOR THE PREPARATION THERE OF
The present invention provides solid state forms of Venetoclax, particularly relates to novel alkali metal salt and/or DMF solvate form of Venetoclax or its salt. The present invention also relates to process for the preparation Venetoclax by using the said solid state form of Venetoclax.
The present invention relates to pharmaceutical composition comprising osimertinib or a pharmaceutically acceptable salt thereof and at least one diluent. The process to prepare such a pharmaceutical composition is also disclosed.
The present invention is directed to process for characterization of Glatiramer acetate. The present invention further relates to process for characterization of Glatiramer acetate using size exclusion chromatography coupled with ultra performance liquid chromatography (SEC- UPLC) and high resolution mass spectrometry (HRMS). The present invention further provides statistical methods for characterizing and classifying Glatiramer acetate.
A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
27.
Polymorph of Riociguat and its process for the preparation
The present invention relates to novel polymorph of riociguat and process for preparing the polymorph. The present invention also relates to the improved process for the preparation of riociguat.
The invention relates to an improved process for the preparation of compound of formula (A), which is an intermediate in the preparation of Obeticholic acid or its analogous compounds thereof.
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
29.
STABLE PHARMACEUTICAL COMPOSITION COMPRISING TELMISARTAN AND AMLODIPINE BESYLATE
The invention relates to a single layer solid oral pharmaceutical composition comprising telmisartan or a pharmaceutically acceptable derivative thereof and at least one calcium channel blocker and process for preparation of the solid oral pharmaceutical composition.
The present invention relates to process for preparation of Brexpiprazole of formula-l and intermediates thereof. The present invention is further directed to process for the preparation of anhydrous form of Brexpiprazole, pharmaceutical compositions containing them.
C07D 333/70 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
31.
PROCESS FOR THE PREPARATION OF (Sp)-SOFOSBUVIR AND INTERMEDIATES THEREOF
The present invention is directed towards process for preparation of an optically pure (Sp)-Sofosbuvir of Formula-(I) and its intermediate namely (Sp)-isomer of isopropyl alanyl phosphoramidate of Formula (III) thereof.
The present invention provides novel crystalline polymorphic form of DL-lactate salt of Panobinostat of Formula-I. This invention also provides process for preparation of crystalline forms of Panobinostat DL-lactate. Further, the present invention relates to a novel pharmaceutically acceptable salts and solid forms of Panobinostat.
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
33.
PROCESS FOR THE PREPARATION OF OLAPARIB AND POLYMORPHS THEREOF
The present invention is directed to process for preparation of Olaparib of formula (I). The present invention further relates to novel polymorphic forms of Olaparib, pharmaceutical compositions containing them, and method of treatment using the same.
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention provides polymorphic forms of Vortioxetine of and its pharmaceutically acceptable salts. Specifically the present invention relates to the novel crystalline forms of Vortioxetine or its pharmaceutically acceptable salts. Moreover, the present invention also provides an amorphous form of Vortioxetine hydrobromide and a stable amorphous co-precipitate of Vortioxetine hydrobromide with pharmaceutically acceptable excipients.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
35.
NOVEL POLYMORPH OF RIOCIGUAT AND ITS PROCESS FOR THE PREPARATION
The present invention relates to novel polymorph of riociguat and process for preparing the polymorph. The present invention also relates to the improved process for the preparation of riociguat.
C07D 471/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
36.
AN IMPROVED PROCESS AND NOVEL POLYMORPHIC FORM OF APREMILAST
The present invention provides an improved process for the preparation of Apremilast using novel intermediates. The present invention also relates to the novel crystalline polymorphic form of Apremilast.
The present invention relates to a solid oral preparations comprising alogliptin and metformin fixed dose combination and to a process for preparation thereof. More particularly, it relates to a solid oral preparation of alogliptin and metformin fixed dose combination formulation which is stable and easy to manufacture.
The present invention provides polymorphic forms of Vortioxetine of and its pharmaceutically acceptable salts. Specifically the present invention relates to the novel crystalline forms of Vortioxetine or its pharmaceutically acceptable salts. Moreover, the present invention also provides an amorphous form of Vortioxetine hydrobromide and a stable amorphous co-precipitate of Vortioxetine hydrobromide with pharmaceutically acceptable excipients.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61P 25/00 - Drugs for disorders of the nervous system
C07D 295/096 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
39.
Process for the preparation of vilazodone hydrochloride and its amorphous form
The present invention relates to an improved process for the preparation of vilazodone hydrochloride and a process for preparation of novel pure amorphous form of vilazodone hydrochloride.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
40.
AN IMPROVED PROCESS FOR THE PREPARATION OF DASATINIB
The present invention relates to a novel synthetic route to N-(2-chloro-6-methylphenyl)- 2-[[6-[4-(2-hydroxyethyl)-l-piperazinyl] -2-methyl-4-pyrimidyl] amino]-5- thiazolformamide of the formula I and also relates to the process for the preparation of novel amorphous forms of dasatinib (formula I).
C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to a stable pharmaceutical composition for sublingual and/or buccal administration comprising asenapine or pharmaceutically acceptable salt thereof, antioxidant. water-soluble polymer, water soluble diluent, disintegrant and optionally one or more pharmaceutically acceptable excipient having improved bioavailability or is bioequivalent to marketed product Saphris®, Sycrest® and process for preparation of same.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
42.
AN IMPROVED PROCESS FOR THE PREPARATION OF TERIFLUNOMIDE
C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
C07C 253/14 - Preparation of carboxylic acid nitriles by reaction of cyanides with halogen-containing compounds with replacement of halogen atoms by cyano groups
C07C 255/23 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
43.
TADALAFIL TABLET COMPOSITION WITH REDUCED DOSE STRENGTH
The Present invention contemplates a pharmaceutical tablet composition of tadalafil with reduced dose strength and is bioequivalent to tadalafil tablet (CIALIS®) product as described in U.S. Federal Food and Drug Administration's New Drug Application No. 021368 approved on Nov 21, 2003. Further the present invention also relates to process for preparing the said tablet composition.
The present invention relates to an improved process for the preparation of Minodronic acid. The present invention particularly relates to a process for the preparation of Minodronic acid from imidazo [1,2-a]pyridine.
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
B65D 81/24 - Adaptations for preventing deterioration or decay of contentsApplications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
A61K 33/00 - Medicinal preparations containing inorganic active ingredients
48.
NOVEL CRYSTALLINE FORM OF AZILSARTAN MEDOXOMIL POTASSIUM
The present invention describes novel crystalline form AL of Azilsartan medoxomil potassium, process for their preparation and pharmaceutical compositions containing them.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present invention relates to a process for the preparation of 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophen-carboxamide (I) by reacting 5-chlorothiphene-2-carbonyl chloride and 4-[4-((S)-4-aminomethyl-2- oxoimidazolidin-1-yl)phenyl]morpholine-3-one hydrochloride in the presence of buffer reagent. (I)
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
An improved process for preparing 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-yl- carboxylicacid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide methanesulfonate salt (dabigatran etexilate mesylate) and a process for purifying dabigatran etexilate mesylate are provided. Further, a process for preparing an intermediate of dabigatran etexilate mesylate of formula (VI) is provided.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to a solid oral preparation of febuxostat and to a process for preparation thereof. More particularly, it relates to a solid oral preparation of febuxostat which is stable and has desired pharmacokinetic properties.
An improved process for the preparation of agomelatine of formula (I) and a new process for the preparation of crystalline form I of agomelatine are provided.
C07C 233/18 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
54.
PROCESS FOR PREPARING ASENAPINE AND SALTS OF INTERMEDIATES THEREOF
A process for preparing substantially pure trans-5-chloro-2-methyl-2,3,3a42b4etrahydro-lH-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole (Asenapine) of formula (I) is provided. The salts of intermediates useful for preparing Asenapine of formula (I) i.e. 5-nitro-2-methyl-2,3,3a,12b-tetrahydro-lH-dibenz [2,3:6,7] oxepino [4,5-c]pyrrole of formula (VIII) and 5-amino-2-methyl-2,3,3a,12b-tetrahydro-lH-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole of formula (DC) are also provided.
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
The present invention relates to a process for the preparation of vilazodone hydrochloride directly from the corresponding carboxylic acid ester derivative by aminolysis. Also part of the invention is a polymorphic form of vilazodone, a process for preparation of novel pure amorphous form of vilazodone hydrochloride and polymorphs of ethyl 5-(4-(4-(5-cyano-lH-indol-3-yl)butyl)piperazin-l-yl)benzofuran-2- carboxylate.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
56.
NOVEL POLYMORPHS OF AZILSARTAN MEDOXOMIL POTASSIUM
Novel forms of Azilsartan medoxomil potassium (Formula I), their preparation and pharmaceutical compositions are provided. New polymorphic forms of Azilsartan medoxomil potassium, their preparation and pharmaceutical compositions are also provided.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Disclosed is a novel polymorph of 3-[(2-{[4-(hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Provided is a stable microcrystalline form of Linezolid and a processes for preparation thereof. Also provided is a multiple packing and vacuum sealed pack comprising Linezolid, or stable microcrystalline form of Linezolid and optionally Linezolid with pharmaceutically acceptable carrier or excipient.
Ivabradine hydrochloride premix and process for preparing the premix are provided. The premix contains ivabradine hydrochloride and premixing agents selected from cellulose derivatives. Also provided is pharmaceutical composition comprising the premix.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention relates Linezolid premix and process for the preparation of the said premix. The present invention also relates to pharmaceutical compositions comprising said Linezolid premix.
The present invention relates to a novel process for the preparation of trans-5-chloro-2- methyl-2,3,3a,12b- tetrahydro-1H-dibenz [2,3:6,7] oxepino[4,5-c] pyrrole (Asenapine) of formula (I). It also relates to novel intermediates i.e. 2-[(E)-2-(2-bromophenyl)ethenyl]-4-nitrophenyl acetate of formula (V), 2-[(3S,4S)-4-(2-bromophenyl)-1-methylpyrrolidin-3-yl]-4-nitrophenyl acetate of formula (VI), 2-[(3S,4S)-4-(2-bromophenyl)-1-methylpyrrolidin-3-yl]-4-nitrophenol of formula (VII), 5-nitro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole of formula (VIII) and 5-amino-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole of formula (IX) are useful for the preparation of Asenapine salts of formula (I).
The present invention relates to the new impurities of Fesoterodine, Fesoterodine symmetric dimer impurity and asymmetric dimer impurity, process for preparing and isolating thereof. The invention also deals with analytical standards and analytical methods used for the control of the production process and final quality of Fesoterodine.
C07C 217/48 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
C07C 219/22 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
C07C 219/28 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
The present invention relates to an improved process for the preparation of Fesoterodine and pharmaceutically acceptable salts thereof. The present invention particularly relates to a process for the preparation of Fesoterodine from O-benzyl tolterodine.
C07C 221/00 - Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
C07C 213/00 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
C07C 213/06 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton from hydroxy amines by reactions involving the etherification or esterification of hydroxy groups
C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
C07C 217/62 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 215/54 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 219/28 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
64.
AN IMPROVED METHOD FOR THE QUANTITATIVE DETERMINATION OF FESOTERODINE FUMARATE
An improved reversed-phase liquid chromatographic (RP-LC) method for the quantitative determination of fesoterodine fumarate is provided. A stability indicating analytical method using the samples generated from forced degradation studies is further provided.
C07C 271/18 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
C07C 269/04 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
C07C 231/14 - Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
66.
IMPROVED PROCESS FOR PREPARATION OF DABIGATRAN ETEXILATE AND ITS NOVEL INTERMEDIATE
Provided are intermediates for preparing dabigatran etexilate i.e. isopropanol solvate of l-methyl-2-[N-(4-amidinophenyl)-aminomethyl] benzimidazol-5-yl-carboxylicacid-N-(2-pyridyl)-N-(2-ethoxy carbonyl ethyl)-amide hydrochloride of formula (Vila) and crystalline form II of l-methyl-2-[N-(4-amidinophenyl)-aminomethyl] benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxy carbonyl ethyl)-amide hydrochloride of formula (VII).
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
A new method of obtaining chemically pure and pharmaceutically acceptable Dabigatran Etexilate or its pharmaceutical acceptable salt having purity at least about 99% is provided, wherein the content of Dabigatran Etexilate individual impurity is less than 0.03-0.15% as measured by HPLC. A method of removing specific impurities that are generated either due to the intrinsic instability of Dabigatran Etexilate or in process of its preparation is provided too.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 235/14 - Radicals substituted by nitrogen atoms
Disclosed are an improved HPLC method for analyzing Linezolid, wherein the mobile phase comprises two or more liquids including buffer and methanol. And the relative concentration of the liquids is varied to a predetermined gradient.
G01N 30/34 - Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
69.
IMPROVED METHOD FOR QUANTITATIVE DETERMINATION OF PRASUGREL HYDROCHLORIDE
Provided are an improved reversed-phase liquid chromatographic method for the quantitative determination of prasugrel hydrochloride and a stability indicating analytical method using the samples generated from forced degradation studies.
Provided are an improved reversed-phase liquid chromatographic method for the quantitative determination of ivabradine hydrochloride and a stability indicating analytical method using the samples generated from forced degradation studies.
Improved processes for obtaining high purity of Dronedarone hydrochloride (chemically known as N-(2-buty1-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide hydrochloride) are provided.
The present invention relates to an improved process for the preparation of Fesoterodine and pharmaceutically acceptable salts thereof. The present invention particularly relates to a process for the preparation of fesoterodine and pharmaceutically acceptable salts thereof which involves use and preparation of R(+) benzyl tolterodine and fumarate salt of R(+)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol.
C07B 57/00 - Separation of optically-active organic compounds
C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
C07C 217/54 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
C07C 219/28 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
The present invention provides a new polymorph Form I of Teriflunomide and a process for preparation thereof. The present invention provides a process for preparation of pure Teriflunomide.
C07C 255/20 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
C07C 255/21 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton the carbon skeleton being further substituted by doubly-bound oxygen atoms
C07C 255/23 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
The present invention relates to an improved process for the preparation of Pentosan polysulfate of formula (I) or salt thereof, wherein R represents -SO3Y, and Y is at least one member selected from the group consisting of H and a pharmaceutically acceptable cation such as sodium, potassium, and magnesium which provides in particular to a narrow distribution low molecular weight, highly sulfated Pentosan polysulfate (in this instance a Xylan).
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
78.
A PROCESS FOR THE PREPARATION OF AMORPHOUS WARFARIN SODIUM
C07D 311/46 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 unsubstituted in the carbocyclic ring
79.
A PROCESS FOR THE PREPARATION OF PRASUGREL HCL SALT
The present invention provides an improved process for the preparation of Linezolid of formula (D. The present invention relates to preparation of intermediate (R)-N-[[3-[3-fluoro-4-morpholinyl] phenyl |-2-oxo-5-oxazolidinyl] methanol of formula (II), Linezolid amine of formula (Ia) and their use in the preparation of Linezolid. The present invention further provides process for the preparation of Form I of Linezolid of formula (I).
The present invention provides a new polymorph Form I of Teriflunomide sodium and a process for preparation thereof. The present invention provides an amorphous form of Teriflunomide sodium and a process for preparation thereof. The present invention provides a new polymorph Form I of Teriflunomide potassium and a process for preparation thereof. The present invention provides an amorphous form of Teriflunomide potassium and a process for preparation thereof. The present invention also provides particle size of Teriflunomide and its salts.
C07C 255/21 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton the carbon skeleton being further substituted by doubly-bound oxygen atoms
The present invention relates to a montelukast hexamethylenediamine, Formule (I). It also relates to a process for the preparation of montelukast hexamethylenediamine and its use for the preparation of Montelukast Sodium.
The present invention relates to provide a process for the preparation of (+)-(R)-Tolterodine-L-tartrate, comprises a step of aminating hydroxyl protected 3-(2-methoxy-5-methylphenyl)-3-phenyl propanol of formula (V) with diisopropylamine in the presence of water to obtain N, N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropyl amine of formula (VI).
C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
C07C 215/54 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 59/68 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
